On March 30, 2023, the Supreme Court of Canada dismissed Pharmascience’s application for leave to appeal (Docket No. 40400) a decision of the Federal Court of Appeal (FCA) upholding the validity of two patents relating to apixaban (Bristol-Myers Squibb’s ELIQUIS). The FCA had dismissed Pharmascience’s appeal of a Federal Court decision upholding the validity of Canadian Patent Nos. 2,461,202 (apixaban and uses thereof in the treatment of thromboembolic disorders) and 2,791,171 (tablet formulations of apixaban) (see previously reported “Federal Court of Appeal upholds validity of two patents relating to ELIQUIS”).
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Supreme Court of Canada agrees to hear challenge to “multi-Crown” class actions under the BC Opioid Damages and Health Care Costs Recovery Act
The Supreme Court of Canada has granted Sanis Health, Shoppers Drug Mart, Sandoz Canada, and McKesson Canada leave to appeal Sandoz Canada v British Columbia, 2023 BCCA 306.Read More -
FCA dismisses appeal, patent not listable against STELARA SNDS
On November 21, 2023, the Federal Court of Appeal (FCA) dismissed Janssen’s appeal: Janssen Inc v Canada (Health), 2023 FCA 229.Read More -
Federal Court of Appeal dismisses appeal relating to Minister of Health’s decision to disclose records pursuant to Access to Information Act request
On November 1, 2023, the Federal Court of Appeal (FCA) dismissed Actial’s appeal from an application for judicial review of the Minister of Health’s decision to disclose records pursuant to a request...Read More